Form 4: MPM BioVentures Reduces Werewolf Therapeutics Stake

MPM BioVentures 2014, a 10% owner and director, reported multiple sales of Werewolf Therapeutics common stock totaling 141,927 shares in late November and early December 2025 under a Rule 10b5-1 plan.

Summary

• MPM BioVentures 2014, L.P., along with related entities, reported the sale of 141,927 shares of Werewolf Therapeutics, Inc. (HOWL) common stock.
• The transactions occurred on November 26, 2025, November 28, 2025, and December 1, 2025.
• Sales were executed at weighted average prices ranging from $0.94 to $0.99 per share.
• All sales were conducted pursuant to a pre-established Rule 10b5-1 trading plan dated September 24, 2025.
• Following these transactions, the reporting persons collectively beneficially own 4,983,843 shares of Werewolf Therapeutics common stock.
• The reporting persons are identified as 10% owners and directors of Werewolf Therapeutics, Inc.

Sentiment

Score: 3

Explanation: The sentiment is negative due to significant insider selling by a 10% owner and director group. While the sales were pre-scheduled under a Rule 10b5-1 plan, the reduction in stake and the sale prices below $1.00 per share are generally perceived as unfavorable signals for the company's stock.

Negatives

• Significant insider selling by a 10% owner and director group, totaling 141,927 shares.
• The sales occurred at weighted average prices below $1.00 per share, specifically $0.98, $0.99, and $0.94.
• A reduction in the beneficial ownership stake of a key institutional investor group.

Risks

• Insider selling, even if pre-scheduled, can be perceived negatively by the market, potentially signaling a lack of confidence or a need for liquidity by the selling entity.
• The sales occurring at prices below $1.00 could indicate a low valuation perception by the selling party.

Future Outlook

The filing does not contain any explicit forward-looking statements or guidance regarding the company's future performance or strategy.

Management Comments

• Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 dated September 24, 2025.
• The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.9328 to $1.01 inclusive (11/26/2025), $0.9681 to $1.01 inclusive (11/28/2025), and $0.905 to $1.00 inclusive (12/01/2025).
• The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• Each Reporting Person disclaims beneficial ownership of the securities except to the extent of his or its pecuniary interest therein.

Industry Context

This Form 4 filing reports an insider transaction and does not provide information directly related to broader industry trends or competitive landscape. However, insider selling in a biotechnology company like Werewolf Therapeutics, Inc. (HOWL) can sometimes be interpreted in the context of sector-specific challenges or opportunities, though no such context is provided here.

Related Party Transactions

• The transactions involve sales of common stock by MPM BioVentures 2014, L.P. and its affiliated entities (MPM BioVentures 2014 (B), L.P., MPM BioVentures 2014 LLC, MPM BioVentures 2014 GP LLC, MPM Asset Management Investors BV2014 LLC, MPM Asset Management LLC, MPM Oncology Innovations Fund, L.P., and UBS Oncology Impact Fund L.P.), which are considered related parties due to their collective 10% ownership and director status in Werewolf Therapeutics, Inc.
• Ansbert Gadicke, who signed the filing, holds managing roles across these various MPM entities, further establishing the related party nature of the reporting group.

Stakeholder Impact

• Shareholders: May interpret the insider selling as a negative signal, potentially leading to downward pressure on the stock price. The reduction in stake by a significant institutional investor could reduce confidence.
• Management: The sales by a director and 10% owner could raise questions about the long-term commitment of key investors, though the 10b5-1 plan mitigates immediate concerns about opportunistic selling.

Key Dates

Recommendation

While the insider selling by MPM BioVentures 2014 and its affiliates is a negative signal, the transactions were executed under a pre-established Rule 10b5-1 plan, suggesting they were not opportunistic. However, the reduction in a significant institutional stake and sales occurring below $1.00 per share warrant caution. Investors should hold and monitor future developments, including any further insider activity, company performance, and strategic updates, before making a definitive buy or sell decision.

Keywords

Werewolf Therapeutics, HOWL, MPM BioVentures, Insider Selling, Form 4, Beneficial Ownership, Rule 10b5-1, Equity Sales, Biotechnology, Institutional Investor